Tripp Forward
Foundation

Progressive and relentless

DMD typically causes loss of walking ability between ages 10–14. With advances in care many boys are walking longer, but the disease continues to progress affecting the heart and lungs over time.

A gene therapy revolution — with gaps

Recent years have brought remarkable breakthroughs. But these treatments were designed for the most common mutations leaving a significant portion of children without options.

Hope is real — and growing

The science of DMD is advancing faster than at any point in history. Non-AAV delivery platforms individualized ASO programs and antibody reduction strategies are opening new doors for children who had none.

Rare within rare

Within the DMD community some children carry mutations so uncommon that even the newer treatments weren't built for them. These children need dedicated research dedicated funding and dedicated advocates.

The boy behind the foundation

Tripp running and laughing outdoors
Tripp, age 6

Tripp is six years old and absolutely full of life. He is a self-described factoid man with an encyclopedic love of animals and a laugh that carries across any yard.

He doesn't know he has DMD yet. And right now, that's exactly how it should be. He deserves the full, unguarded joy of being six, and he has it. He runs. He plays. He is here, fully and joyfully. When he starts asking bigger questions, we'll answer them honestly. But the disease will never define him, and we are determined that his story won't follow the path that diagnosis alone might suggest.

What we do know is that his specific mutation places him within a smaller group still. Children whose genetic profile is rare even within DMD, sitting outside the reach of the treatments that have brought hope to many other families. The window when early intervention can make the greatest difference is now.

His diagnosis moved us to act, not just for him, but for every child in the DMD community whose mutation leaves them waiting for science to catch up. We are hopeful, genuinely and stubbornly hopeful, that the work of this foundation and the researchers it supports will help bend the trajectory of what DMD "normally" looks like, for Tripp and for every child who comes after him.

Tripp is the reason this foundation exists. Every child like him is the reason it will keep going.

100% of every contribution goes directly to funding the research  —  no overhead, no exceptions

Where your dollars go

We fund research at the intersection of non-AAV delivery, early-exon mutation science and antibody barrier reduction. These are the areas that matter most for children like Tripp and are least served by the current pipeline. Every grant is directed, specific and tied to a named researcher and a named outcome.

Non-AAV delivery

Funding platforms that deliver therapeutic payloads to muscle without viral vectors, reaching children who cannot receive AAV-based therapies due to pre-existing antibodies.

Early-exon exon skipping

Supporting individualized ASO and PMO programs designed for rare duplication and early-exon mutations — the mutations the approved exon-skipping drugs weren't built for.

Antibody reduction

Funding protocols that reduce or clear AAV antibodies — creating a window for gene therapy eligibility in children who would otherwise be excluded from every current trial.

Give today

100% of every contribution goes directly to funding the research.

Every dollar goes directly to research. We are committed to lean operations and the vast majority of every contribution funds the science, not the overhead. Donations are processed through Givebutter and directed to our Raymond James Charitable fund, with full tax documentation provided.

Ready to move forward?

Every gift, at any level, moves the science forward for Tripp and every child still waiting.

Give on Givebutter

For questions about giving, contact rachel@trippforward.org

A letter from Tripp's parents

When Tripp was diagnosed, we did what most parents do. We went looking for answers. What we found was a research landscape that had made extraordinary progress for many DMD families and almost none for ours.

He was diagnosed with Duchenne muscular dystrophy — and his specific mutation places him within a smaller group still: children whose genetic profile is rare even within DMD, sitting outside the reach of the treatments that have brought hope to many other families.

We built Tripp Forward Foundation because we couldn't find the organization that was doing exactly this work, funding the non-AAV and early-exon research that reaches children like Tripp. So we decided to build it ourselves.

This foundation is Tripp's. But the research it funds belongs to every family still waiting for a treatment that fits their child.

Thank you for being part of moving forward.

Rachel & Jason